Furthermore, it has been found that IL-33 promotes EMT and tumor progression by regulating the expression of CCL2 and recruiting Tregs through the TGF-β signaling pathway in ESCC [77]. This evidence concerns the gene CCL2 and esophageal squamous cell carcinoma.